Gene

SETD2

SET domain containing 2, histone lysine methyltransferase

Explore in graph →CI-GENE-00030395HGNC:18420 ENSG00000181555 NCBI 29072 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (3)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BAP1 Mutation + NF2 Mutation + SETD2 MutationBAP1 SETD2 NF21
Samotolisib	Malignant Mesothelioma	Predictive	B	Supports Sensitivity Response	3	submitted	EID11742 In this study, 42 patients with malignant pleural or peritoneal mesothelioma were treated with single-agent LY3023414 (Samotolisib). Among the 42 patients, 11 had BAP1 mutations, while SETD2 and NF2 m… (full text at CIViC) PMID 33660194 · Zauderer et al., 2021 · Open in CIViC	civic
SETD2 Loss2
Anti-PD1 Monoclonal Antibody + ATR InhibitorCombination	Clear Cell Renal Cell Carcinoma	Predictive	D	Supports

Cohorts

Alteration frequency by cohort (200)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved200 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Kidney Renal Clear Cell Carcinoma TCGA-KIRC	Clear Cell Renal Cell Carcinoma

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.